As of Jun 23
| -0.16 / -9.58%|
The 2 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate represents a +131.79% increase from the last price of 1.51.
The current consensus among 3 polled investment analysts is to Hold stock in Endocyte Inc. This rating has held steady since June, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.